Clinical significance of cyclooxygenase-2 (COX-2) in multiple myeloma | Zendy

Marianne Tinguely | Zendy; Sonia Vallet | Zendy; B Jenni | Zendy; Mathias WitzensHarig | Zendy; Gunhild Mechtersheimer | Zendy; AD Ho | Zendy; H. Goldschmidt | Zendy; D Jger | Zendy; Mario Boccadoro | Zendy; Marco Ladetto | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Clinical significance of cyclooxygenase-2 (COX-2) in multiple myeloma

Author(s) -

Marianne Tinguely,

Sonia Vallet,

B Jenni,

Mathias WitzensHarig,

Gunhild Mechtersheimer,

AD Ho,

H. Goldschmidt,

D Jger,

Mario Boccadoro,

Marco Ladetto

Publication year - 2006

Publication title -

schweizerische medizinische wochenschrift

Language(s) - English

Resource type - Journals

ISSN - 0036-7672

DOI - 10.4414/smw.2006.11467

Subject(s) - medicine , proportional hazards model , multiple myeloma , cyclooxygenase , immunohistochemistry , clinical significance , stage (stratigraphy) , pathogenesis , bone marrow , survival analysis , pathology , oncology , enzyme , biology , biochemistry , paleontology

Several biological and clinical considerations suggest the involvement of cyclooxygenase-2 (COX-2), the key enzyme of prostaglandin (PG) synthesis, in the pathogenesis and progression of haematological malignancies. Despite the wealth of data concerning COX-2 expression, only limited information is available on multiple myeloma (MM). Using standard immunohistochemistry we therefore evaluated COX-2 protein expression in samples from 57 patients with a primary diagnosis of MM. Time to progression and a variety of clinicopathological features were evaluated by the Kaplan-Meier method and the Cox regression model. In addition, COX-2 expression was evaluated by staining bone marrow from healthy donors and 11 patients with MGUS. Overall, 31 MM samples (54%) expressed COX-2. Positivity for COX-2 was unrelated to stage or clinical or molecular features of the disease. However, patients with COX-2 positive tumours experienced a significantly shorter time to progression (17 vs 30 months, p = 0.037). In summary, COX-2 is frequently expressed in MM and correlates with shorter progression-free survival.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research